vorasidenib
servier
['vorasidenib']
patients with grade 2 idh-mutant glioma experienced a 61% reduced risk of progression or desk when treated with vorasidenib. #asco23 #btsm 
Cancer updates, research and education for patients with cancer, survivors and their caregivers to become empowered advocates in their journey.